Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Product revenue, net | $116,357 | $88,183 |
| Operating expenses | ||
| Cost of goods sold | 6,323 | 5,028 |
| Research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Total operating expenses | 62,668 | 51,931 |
| Income from operations | 53,689 | 36,252 |
| Other income |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s R&D?
- Krystal Biotech, Inc. (KRYS) reported R&D of $15.33M in Q1 2026.
- How has Krystal Biotech, Inc.'s R&D changed year-over-year?
- Krystal Biotech, Inc.'s R&D increased by 7.5% year-over-year, from $14.26M to $15.33M.
- What is the long-term trend for Krystal Biotech, Inc.'s R&D?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s R&D has grown at a 20.1% compound annual growth rate (CAGR), from $27.88M to $58.05M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Krystal Biotech, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude